TTP and ODx to Develop New Technology Addressing Antibiotic Resistance
Product News May 01, 2020
TTP plc (TTP), an independent technology and product development company, has announced today that it has partnered with ODx (ODx Innovations Ltd), a company committed to developing a system for assessing urinary tract infections (UTIs). The collaboration is focused on bringing ODx’ system to market through TTP’s Desktop Biology service.
The ODx system offers the potential to revolutionize the turnaround time for the assessment of suspected UTIs, reduce the use of antibiotics and provider faster access to optimal antimicrobial therapy.
ODx’ proprietary detection technique relies on subjecting urine samples to an antibiotic panel to assess the effectiveness of each compound at killing bacteria. TTP and ODx have further refined and developed this technology to provide rapid and multiplexed analysis. The test passes light through samples, monitoring optical response over time to investigate bacterial growth, and if/how this is affected by the presence of different antibiotics. The multiplex cartridge allows for different antibiotic panels and concentrations to be tested, depending upon clinical settings and geography.
Once released, it is expected the system will be placed in doctors’ offices, hospital outpatient clinics and potentially pharmacies. This will help assess suspected UTIs at the point of care, ensuring the most appropriate antibiotics are identified as quickly as possible. Facilitating the development of personalized treatment plans, the system will help tackle antibiotic resistance by reducing un-necessary prescriptions, whilst making sure that antibiotic courses have the maximum possible effectiveness for a given patient.
The system is being co-developed through TTP’s Desktop Biology service, which was launched in 2016 to help companies accelerate the development of their assay to a product for use in diagnostics or research. TTP has been ODx’ development partner since early 2019, enabling their detection technology through a multi skilled team from both parties covering biology, microfluidics, optics, human factors and engineering capabilities.